FLT

The fms-like tyrosine kinase (Fit) is a transmembrane receptor in the tyrosine kinase family. Expression of fit complementary DNA in COS cells conferred specific, high-affinity binding of vascular endothelial growth factor, also known as vascular permeability factor (VEGF-VPF).

Cat. No.	Product name	CAS No.	Purity
T73549	RSH-7	2764609-97-2	98.31%
T73549	RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptos...
T6115	Fostamatinib	901119-35-5	98.24%
T6115	Fostamatinib (R788)(IC50 of 41 nM), which is a prodrug of the active metabolite R406, is a Syk inhibitor. It does not work on Lyn.
T0374	Sunitinib Malate	341031-54-7	98.23%
T0374	Sunitinib Malate (Sunitinib) is an indolinone-based tyrosine kinase inhibitor. It blocks the tyrosine kinase activities of VEGFR2, PDGFRβ (IC50: 80/2 nM), and c-...
T41003	KG5	877874-85-6	98.2%
T41003	KG5 is a dual allosteric inhibitor of PDGFRβ and B-Raf with a Kd of 520 nM and 300 nM for PDGFRβ and PDGFRα. KG5 inhibits FLT3, KIT, and c-Raf with anticancer an...
T4053	AST 487	630124-46-8	98.17%
T4053	AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
T71973	Gilteritinib hemifumarate	1254053-84-3	98.07%
T71973	Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of rel...
TQ0059	Ilorasertib	1227939-82-3	98.03%
TQ0059	Ilorasertib (ABT-348) (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120 nM/7 nM/1 nM). It als...
T1938	FLT3-IN-2	923562-23-6	98%
T1938	FLT3-IN-2 is an FLT3 inhibitor (IC50<1 μM).
T2358	ENMD-2076	934353-76-1	98%
T2358	ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.
TQ0166	Tesevatinib	781613-23-8	97.89%
TQ0166	Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4)....
T64370	JI6	856436-16-3	97.74%
T64370	JI6 (JAK3 Inhibitor VI) is a potent, selective and orally active FLT3 inhibitor. JI6 exhibits IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, ...
T1836	AZD2932	883986-34-3	97.71%
T1836	AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFβ, Flt-3, and c-Kit.
T16750	Rigosertib	592542-59-1	97.33%
T16750	Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer a...
T38562	AKN-028	1175017-90-9	97.3%
T38562	AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.
T5164	Cabozantinib hydrochloride	1817759-42-4	97.09%
T5164	Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM...
T13564	AZ7550	1421373-99-0	97.07%
T13564	AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
T6458	CYC-116	693228-63-6	96.6%
T6458	CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active a...
T15335	FN-1501	1429515-59-2	96.35%
T15335	FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1...
T35570	Chiauranib	1256349-48-0	96.25%
T35570	Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects. Chiauranib potently inhibits the angiogenesis-related k...
T3621	Brigatinib	1197953-54-0	100%
T3621	Brigatinib (AP-26113) is a highly potent and selective ALK inhibitor.